Insitro Founder Daphne Koller on AI's Real Promise and Limits in Drug Discovery
tomchapin · x · 2026-08-06
Daphne Koller, founder of Insitro, published a deep dive essay exploring the actual role of AI in drug discovery and development. As one of the most AI-driven biotech companies globally, Insitro extensively uses AI agents and tools across its internal workflows.
The core value of the essay lies in Insitro being one of the few AI-biotech firms genuinely committed to developing novel medicines against novel targets. Having experienced firsthand how grueling every step of this process is, Koller outlines thoughtful reasoning on where AI can work magic and where its current limitations persist.
Related event: Insitro Founder Highlights Bottlenecks in Bio-AI(4 posts)→
More from Research
- Multimodal Embeddings Reshape RAG: Ditch Lossy Text Conversion for Native Retrieval — CShorten30 · 2026-08-07
- Deep Dive: What Comes After Large Language Models? — bigdata · 2026-08-07
- Brown postdoc program expands with ARIA, a $20M NSF institute for trustworthy AI assistants — tserre · 2026-08-07
- Scholars Propose AI Pre-Review for Papers: Automated Code Replication and Error Checking — Afinetheorem · 2026-08-07
- Brown University postdoc fellowships in computational brain science, bridging AI and neuroscience — tserre · 2026-08-07
- Exploring Best Practices for Training WAN 2.2 Motion LoRAs — fluvialcrunchy · 2026-08-07